NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

The next wave of artificial intelligence infrastructure won't come from tech giants alone—but from nimble operators who already own the power. Take Digi Power X Inc (NASDAQ:DGXX, TSX-V:DGX), a Miami-based, NASDAQ- and Toronto-listed company that has spent the past eight years mining Bitcoin and quietly building out a power generation footprint. Now, it's shifting gears, rebranding to become what CEO Michel Amar calls "a power infrastructure company" with a focus on Tier 3 NeoCloud AI data centers. Earlier t ...

德源药业 20250722 摘要 德源药业确立仿创结合战略，仿制药业务以糖尿病药物为主，并向并发 症、心血管疾病等领域延伸。2024 年新获批的 7 个批件中有 4 个中标 第 10 批集采，有望借助集采迅速放量，其余品种将参与集采续标或地 方联盟采购。 公司创新药业务处于投入期，计划每年取得一个 IND 批件，2025 年预 计投入 8,500 万元用于 DYX 116 的一期临床和 216 临床前费用。DYX 116 是一款 GRP-1 三靶点受体激动剂，目前已启动一期临床试验，预计 2025 年底完成。 公司预计 2025-2027 年归母净利润分别为 1.92 亿元、2.18 亿元和 2 亿元，对应 PE 分别为 21 倍、19 倍和 20 倍。考虑到可比公司估值，给 予德源药业 33 倍 PE，对应目标市值 64 亿，较当前股价有上涨空间。 中国糖尿病患者约 1.7 亿人，高血压患者约 3.9 亿人，慢性代谢性疾病 市场潜力巨大。相对平价的仿制药和创新药将长期并存，共同驱动用药 需求增长，公司在该领域有广阔发展前景。 Q&A 德源药业的基本情况和发展历程是什么？ 德源药业成立于 2004 年，专注于 ...

Key Takeaways SRPT is pausing U.S. Elevidys shipments to complete safety labeling changes and respond to FDA requests. The move follows patient deaths linked to ALF in studies using the same AAVrh74 gene therapy vector. SRPT expects significant financial impact in quarters ahead as Elevidys drove over half of its Q1 revenues.Shares of Sarepta Therapeutics (SRPT) are declining in the pre-market hours today after the announcement that it will voluntarily and temporarily halt all U.S. shipments of Elevidys, ...

Invesco (IVZ) Q2 2025 Earnings Call July 22, 2025 09:00 AM ET Speaker0Thank you for standing by and welcome to Invesco's Second Quarter Earnings Conference Call. All participants will be in a listen only mode until the question and answer session. This call will last one hour. To allow more participants to ask questions, one question and a follow-up can be submitted per participant. As a reminder, today's call is being recorded.Now I'd to turn the call over to Greg Ketron, Invesco's Head of Investor Relatio ...

The Coca-Cola Company (KO) Q2 2025 Earnings Call July 22, 2025 08:30 AM ET Company ParticipantsRobin Halpern - VP & Head - IRJames Quincey - Chairman, CEO & DirectorJohn Murphy - President & CFOLauren Lieberman - Managing DirectorDara Mohsenian - Managing Director - US Beverage/Household Products SectorsFilippo Falorni - Director - Equity ResearchBonnie Herzog - Managing Director Kaumil Gajrawala - Managing DirectorRobert Ottenstein - Senior MD & PartnerAndrea Teixeira - Managing DirectorPeter Galbo - Direc ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BellRing Brands, Inc. (NYSE: BRBR) for potential violations of the federal securities laws. If you invested in BellRing, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/bellring-brands-inc-class-action-lawsuit. Why is BellRing being Investigated? BellRing operates in the convenient nutrition category. The Company’s pr ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

传统软件开发需要产品、设计、研发多个团队接力协作，涉及产品规划、设计、研发和部署多个环节，AI编程正在改变软件开发范式。比如，在电商活动 页开发中，传统方式需要2天完成1个页面，使用这一工作台后整个过程不到2小时，效率提升超过10倍：产品经理文字输入需求，10分钟生成初版；设计师 通过截图调整样式，1小时定稿；开发人员快速转换成代码，30分钟即开发出网站。 国内厂商在AI编程上再加码。7月22日，腾讯云宣布开发工作台CodeBuddy IDE开启内测，实现"产品-设计-研发部署"全流程AI一体化。 据悉，这一工作台国际版整合了Claude、GPT、Gemini等顶尖AI模型，国内版支持腾讯混元、DeepSeek等模型，聚焦"对话即编程"，用户无需一行代码，仅 需用自然语言对话就能实现应用从产品构想、设计、开发部署的全流程，让非技术背景的从业者也能快速实现创意，提升软件开发效率。 "我们将会看到越来越多的独立开发者出现，这是一个增量市场。"腾讯云开发者产品总经理刘毅表示，AI编程不仅大大提升了软件工程开发的效率，也降低 了软件开发的门槛。 记者：袁璐 如遇作品内容、版权等问题，请在相关文章刊发之日起30日内与本 ...

腾讯AI编程产品CodeBuddy发布会 - 公司推出首个"产品-设计-研发部署"全流程AI一体化开发工作台CodeBuddy IDE，从插件形态升级为独立AI IDE [4][5][7] - 产品主打"产设研一体"概念，针对独立开发者及非技术背景用户设计，集成设计组件库、文档生成及后端部署功能 [5][15][16] 核心功能亮点 - **国际版支持Claude4模型且免费**，提供全球化服务能力 [10] - **Plan mode模式**可自动生成PRD/TRD/DRD文档，并基于文档生成网页及部署后端，实现全流程自动化 [11][31][40] - **Figma设计稿一键转网页**功能，转换精度较高仅存在局部样式拉伸问题 [12][28][29] - **自然语言UI微调**支持对HTML元素实时修改（如渐变、圆角等样式调整） [14][20][22] - **集成主流技术栈**包括腾讯云开发CloudBase与Supabase，降低后端搭建门槛 [15][22][24] 产品差异化定位 - 区别于纯开发者工具，聚焦产品经理、设计师等非技术角色，内置PRD模板、Figma对接等跨职能模块 [15][16][31] - 演示案例显示可10分钟内完成"宝可梦图鉴网站"从需求分析到部署上线的全流程 [17][19][26] - 公司提出AI编程将分化为"氛围编程"（非技术人员主导）与"规约编程"（专业团队协作）两种范式 [41] 行业影响与竞争态势 - 产品呼应AI对设计/影视等行业的影响逻辑：简单场景AI主导，复杂场景AI辅助 [43][44] - 公司呼吁行业加速AI编程及Agent领域竞争，类比"外卖补贴大战"以推动技术进步 [52][53][54] 当前进展 - 产品处于内测阶段，需邀请码体验，发布会现场发放50个邀请码用于测试 [45][48][51]